291 related articles for article (PubMed ID: 24710357)
1. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members.
Beigel F; Friedrich M; Probst C; Sotlar K; Göke B; Diegelmann J; Brand S
PLoS One; 2014; 9(4):e93498. PubMed ID: 24710357
[TBL] [Abstract][Full Text] [Related]
2. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.
Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA
J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849
[TBL] [Abstract][Full Text] [Related]
3. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
[TBL] [Abstract][Full Text] [Related]
4. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration.
Brand S; Beigel F; Olszak T; Zitzmann K; Eichhorst ST; Otte JM; Diepolder H; Marquardt A; Jagla W; Popp A; Leclair S; Herrmann K; Seiderer J; Ochsenkühn T; Göke B; Auernhammer CJ; Dambacher J
Am J Physiol Gastrointest Liver Physiol; 2006 Apr; 290(4):G827-38. PubMed ID: 16537974
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease.
Dambacher J; Beigel F; Seiderer J; Haller D; Göke B; Auernhammer CJ; Brand S
Gut; 2007 Sep; 56(9):1257-65. PubMed ID: 17449633
[TBL] [Abstract][Full Text] [Related]
6. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.
Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087
[TBL] [Abstract][Full Text] [Related]
7. Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways.
Wang H; Lei L; Hu J; Li Y
Exp Physiol; 2020 Jul; 105(7):1151-1158. PubMed ID: 32359099
[TBL] [Abstract][Full Text] [Related]
8. A dual role for oncostatin M signaling in the differentiation and death of mammary epithelial cells in vivo.
Tiffen PG; Omidvar N; Marquez-Almuina N; Croston D; Watson CJ; Clarkson RW
Mol Endocrinol; 2008 Dec; 22(12):2677-88. PubMed ID: 18927239
[TBL] [Abstract][Full Text] [Related]
9. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
10. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.
Fossey SL; Bear MD; Kisseberth WC; Pennell M; London CA
BMC Cancer; 2011 Apr; 11():125. PubMed ID: 21481226
[TBL] [Abstract][Full Text] [Related]
11. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ.
Demyanets S; Kaun C; Rychli K; Pfaffenberger S; Kastl SP; Hohensinner PJ; Rega G; Katsaros KM; Afonyushkin T; Bochkov VN; Paireder M; Huk I; Maurer G; Huber K; Wojta J
Basic Res Cardiol; 2011 Mar; 106(2):217-31. PubMed ID: 21174212
[TBL] [Abstract][Full Text] [Related]
12. Oncostatin M is a growth factor for Ewing sarcoma.
David E; Tirode F; Baud'huin M; Guihard P; Laud K; Delattre O; Heymann MF; Heymann D; Redini F; Blanchard F
Am J Pathol; 2012 Nov; 181(5):1782-95. PubMed ID: 22982441
[TBL] [Abstract][Full Text] [Related]
13. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts.
Kokkotis G; Filidou E; Tarapatzi G; Spathakis M; Kandilogiannakis L; Dovrolis N; Arvanitidis K; Drygiannakis I; Valatas V; Vradelis S; Manolopoulos VG; Paspaliaris V; Kolios G; Bamias G
Inflamm Bowel Dis; 2024 May; ():. PubMed ID: 38717842
[TBL] [Abstract][Full Text] [Related]
15. Effects of azathioprine and its metabolites on repair mechanisms of the intestinal epithelium in vitro.
Schroll S; Sarlette A; Ahrens K; Manns MP; Göke M
Regul Pept; 2005 Nov; 131(1-3):1-11. PubMed ID: 16122821
[TBL] [Abstract][Full Text] [Related]
16. A novel role for interleukin-27 (IL-27) as mediator of intestinal epithelial barrier protection mediated via differential signal transducer and activator of transcription (STAT) protein signaling and induction of antibacterial and anti-inflammatory proteins.
Diegelmann J; Olszak T; Göke B; Blumberg RS; Brand S
J Biol Chem; 2012 Jan; 287(1):286-298. PubMed ID: 22069308
[TBL] [Abstract][Full Text] [Related]
17. Murine Oncostatin M Has Opposing Effects on the Proliferation of OP9 Bone Marrow Stromal Cells and NIH/3T3 Fibroblasts Signaling through the OSMR.
Jakob L; Müller TA; Rassner M; Kleinfelder H; Veratti P; Mitschke J; Miething C; Oostendorp RAJ; Pfeifer D; Waterhouse M; Duyster J
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769079
[TBL] [Abstract][Full Text] [Related]
18. Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation.
Boniface K; Diveu C; Morel F; Pedretti N; Froger J; Ravon E; Garcia M; Venereau E; Preisser L; Guignouard E; Guillet G; Dagregorio G; Pène J; Moles JP; Yssel H; Chevalier S; Bernard FX; Gascan H; Lecron JC
J Immunol; 2007 Apr; 178(7):4615-22. PubMed ID: 17372020
[TBL] [Abstract][Full Text] [Related]
19. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
West NR; Hegazy AN; Owens BMJ; Bullers SJ; Linggi B; Buonocore S; Coccia M; Görtz D; This S; Stockenhuber K; Pott J; Friedrich M; Ryzhakov G; Baribaud F; Brodmerkel C; Cieluch C; Rahman N; Müller-Newen G; Owens RJ; Kühl AA; Maloy KJ; Plevy SE; ; Keshav S; Travis SPL; Powrie F
Nat Med; 2017 May; 23(5):579-589. PubMed ID: 28368383
[TBL] [Abstract][Full Text] [Related]
20. STAT3 and ERK Signaling Pathways Are Implicated in the Invasion Activity by Oncostatin M through Induction of Matrix Metalloproteinases 2 and 9.
Ko HS; Park BJ; Choi SK; Kang HK; Kim A; Kim HS; Park IY; Shin JC
Yonsei Med J; 2016 May; 57(3):761-8. PubMed ID: 26996579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
